Alpha-fetoprotein (AFP)
Alpha-fetoprotein (AFP) is a glycoprotein and well-established serum tumor marker, best known for its clinical association with hepatocellular carcinoma (HCC).
Alpha-fetoprotein (AFP) is a glycoprotein and well-established serum tumor marker, best known for its clinical association with hepatocellular carcinoma (HCC). It is also used in the evaluation of other AFP-producing malignancies, including alpha-fetoprotein-producing gastric cancer, where elevated serum AFP can correlate with tumor stage and prognosis. In routine practice, AFP is primarily valued as a biomarker for detection, risk stratification, and disease monitoring rather than as a standalone diagnostic test.
Beyond its biomarker role, recent research has increasingly examined AFP as a biologically active molecule in cancer. In hepatocellular carcinoma, AFP has been investigated as a regulator of cancer stemness and tumor progression, including signaling through the PI3K/Akt signaling pathway. This broader functional perspective has prompted studies of AFP in relation to tumor biology, glycoprotein recognition, and assay development, alongside related cancer markers such as Carcinoembryonic antigen (CEA), Epithelial Cell Adhesion Molecule (EpCAM), CD44, Human epidermal growth factor receptor 2 (HER2), and TP53.
Where the papers sit
18 papers from the last 6 months study Alpha-fetoprotein (AFP) directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 1 observational · 13 human data · 1 preclinical · 2 unclassified
Themes 4 themes · 1 paradigm shift · 1 new direction
-
AFP Biosensor Development
AFP measurement is moving toward ultrasensitive, multiplexed and potentially point-of-care biosensors. Gold nanoparticles, nanowires, metal-organic frameworks, aptamers, quantum dots and SERS or electrochemical readouts provide signal amplification and lower detection limits. Specificity, linear range and self-referencing performance recur across platforms. Clinical validation and translation beyond laboratory prototypes remain open.
8 papers · 44.4%
-
HCC Biomarker Assessment
AFP-based panels are moving toward earlier HCC detection and recurrence-risk stratification rather than AFP alone. PIVKA-II, AKR1B10 and routine clinical variables help address AFP-negative or early-stage disease, with sensitivity, specificity and AUC as recurring endpoints. AFP status and LMR dynamics also recur during atezolizumab/bevacizumab treatment. A neoantigen vaccine is an isolated preclinical extension rather than a shared direction.
5 papers · 27.8%
-
CRISPR Biosensing of Liver Cancer
HCC biomarker detection is moving toward compact CRISPR/Cas12a platforms with amplified, rapid signal generation. DNA triangular prisms, Mn-cysteine laccase mimics and ferroelectric photoelectrochemical designs support electrochemical or immunoassay readouts. The recurring goals are high sensitivity, low background and operation across practical temperatures or without external power. Whether these systems outperform established ELISA in clinical samples remains open.
3 papers · 16.7%
-
Omics Biomarker Discovery
Biomarker discovery is shifting toward integrated proteomic, glycoproteomic and metabolomic profiles analyzed with machine learning. Random-forest models and ROC-based evaluation are used to prioritize candidates for gestational diabetes and HCC. AFP appears within broader molecular signatures rather than as a standalone marker. Reproducibility and clinical validation remain the main unresolved steps.
2 papers · 11.1%
AFP alone is inadequate for reliable hepatocellular carcinoma detection
The study integrating PIVKA-II with AFP and clinical variables in HCC, the multicentre study of AKR1B10 in early and AFP-negative HCC, and the serum glycoproteomics study distinguishing HCC from cirrhosis each found that AFP’s diagnostic performance is incomplete or inconsistent and that complementary molecular markers or multimarker models improve discrimination 42644494Aug 42363436Jun 42304605Jun. This overturns an AFP-centred diagnostic approach: AFP should not be treated as a sufficient standalone indicator, particularly for early, AFP-negative, or cirrhotic-background HCC, and detection should instead rely on integrated marker panels or alternative biomarkers.
AFP is used as a therapeutic neoantigen to generate antitumor immunity
The bivalent mRNA neoantigen vaccine study in mice with HCC used AFP, together with Glypican 3, as an encoded tumor antigen delivered to splenic dendritic cells, eliciting AFP-specific cytotoxic T lymphocytes and protection against tumor challenge 42442546Jul. This assigns AFP a role beyond diagnosis, prognosis, or assay detection: it becomes an immunotherapeutic target whose presentation is intended to eradicate AFP-expressing HCC.
Papers
The 18 papers from the last 6 months that study Alpha-fetoprotein (AFP) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
AFP Biosensor Development (8)
- Highly sensitive electrochemical immunosensor for alpha-fetoprotein detection based on trimetallic metal-organic framework nanozymes with peroxidase-like activity. Mikrochimica acta · 13 Sept 2026 PMID 42733036
- Ion-Driven Cyclic Hotspot Modulation for Tunable SERS Detection of Alpha-Fetoprotein. Analytical chemistry · 18 Aug 2026 PMID 42610897
- A label-free membrane-based biosensor array with AuNP-modified PDMS for sensitive and specific detection of alpha-fetoprotein. Analytical and bioanalytical chemistry · 3 Jul 2026 PMID 42399503
- 7-(Diethylamino)coumarin-3-carboxylic acid functionalized aptamers induced photoelectrochemical/fluorescence dual-mode microfluidic sensor for integrated detection of three liver cancer biomarkers. Biosensors & bioelectronics · 29 Jun 2026 PMID 42372685
- Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levels. Cancer prevention research (Philadelphia, Pa.) · 18 Jun 2026 PMID 42310898
- Simultaneous multi-biomarker detection: streptavidin-biotin mediated high-quality quantum dot immunosensor with signal amplification. Analytica chimica acta · 26 May 2026 PMID 42191297
- DNA Tetrahedron-Mediated Sensing Platform on a Single Gold Nanowire: Special Signal Amplification, Self-Referencing Capability, and Cross-Validated Exosome Detection for Liver Cancer Liquid Biopsy. ACS sensors · 26 May 2026 PMID 42190059
- Glycoprotein biosensor boosted by signal amplification of heparin polysaccharide and insights into glycan-lectin recognition. Mikrochimica acta · 22 May 2026 PMID 42174235
HCC Biomarker Assessment (5)
- Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674689
- Integrating Abnormal Prothrombin (PIVKA-II), Alpha-Fetoprotein, and Routine Clinical Variables for Early Detection of Hepatocellular Carcinoma. Journal of visualized experiments : JoVE · 26 Aug 2026 PMID 42644494
- A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice. Journal of controlled release : official journal of the Controlled Release Society · 13 Jul 2026 PMID 42442546
- Log-transformed α-Fetoprotein and Des-γ-carboxy Prothrombin Predict Early Recurrence After Hepatectomy for Hepatocellular Carcinoma. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379778
- Diagnostic Performance of Serum AKR1B10 in Early-Stage and AFP-Negative Hepatocellular Carcinoma: A Multicentre Study. Liver international : official journal of the International Association for the Study of the Liver · 27 Jun 2026 PMID 42363436
CRISPR Biosensing of Liver Cancer (3)
- Ligand-Engineered Mn-Cysteine as a Potent Laccase Mimic for CRISPR/Cas12a Electrochemical Biosensing of Hepatocellular Carcinoma Biomarkers. ACS nano · 18 Aug 2026 PMID 42611239
- An Entropy-Driven Autocatalysis-Regulated Signal-On CRISPR/Cas12a Biosensor Supported by DNA Triangular Prism Scaffold. Analytical chemistry · 23 Jun 2026 PMID 42335458
- Overriding n-Type Surface Depletion via Ferroelectric Pumping for Self-Powered Cathodic Photoelectrochemical Immunoassay. Analytical chemistry · 19 Jun 2026 PMID 42319751
Omics Biomarker Discovery (2)
- Integrative Proteomics-Metabolomics Profiling of Umbilical Cord Plasma With Machine Learning Reveals Candidate Biomarkers for Gestational Diabetes Mellitus. Diabetes, obesity & metabolism · 17 Aug 2026 PMID 42608332
- Glycoproteome Profiling of Human Serum for Hepatocellular Carcinoma Biomarker Discovery. Journal of proteome research · 17 Jun 2026 PMID 42304605
By study type
Clinical trials (1)
- Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levels. Cancer prevention research (Philadelphia, Pa.) · 18 Jun 2026 PMID 42310898
Observational studies and case reports (1)
- Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674689
Human data, design not indexed (13)
- Highly sensitive electrochemical immunosensor for alpha-fetoprotein detection based on trimetallic metal-organic framework nanozymes with peroxidase-like activity. Mikrochimica acta · 13 Sept 2026 PMID 42733036
- Integrating Abnormal Prothrombin (PIVKA-II), Alpha-Fetoprotein, and Routine Clinical Variables for Early Detection of Hepatocellular Carcinoma. Journal of visualized experiments : JoVE · 26 Aug 2026 PMID 42644494
- Ligand-Engineered Mn-Cysteine as a Potent Laccase Mimic for CRISPR/Cas12a Electrochemical Biosensing of Hepatocellular Carcinoma Biomarkers. ACS nano · 18 Aug 2026 PMID 42611239
- Ion-Driven Cyclic Hotspot Modulation for Tunable SERS Detection of Alpha-Fetoprotein. Analytical chemistry · 18 Aug 2026 PMID 42610897
- A label-free membrane-based biosensor array with AuNP-modified PDMS for sensitive and specific detection of alpha-fetoprotein. Analytical and bioanalytical chemistry · 3 Jul 2026 PMID 42399503
- Log-transformed α-Fetoprotein and Des-γ-carboxy Prothrombin Predict Early Recurrence After Hepatectomy for Hepatocellular Carcinoma. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379778
- 7-(Diethylamino)coumarin-3-carboxylic acid functionalized aptamers induced photoelectrochemical/fluorescence dual-mode microfluidic sensor for integrated detection of three liver cancer biomarkers. Biosensors & bioelectronics · 29 Jun 2026 PMID 42372685
- Diagnostic Performance of Serum AKR1B10 in Early-Stage and AFP-Negative Hepatocellular Carcinoma: A Multicentre Study. Liver international : official journal of the International Association for the Study of the Liver · 27 Jun 2026 PMID 42363436
- An Entropy-Driven Autocatalysis-Regulated Signal-On CRISPR/Cas12a Biosensor Supported by DNA Triangular Prism Scaffold. Analytical chemistry · 23 Jun 2026 PMID 42335458
- Overriding n-Type Surface Depletion via Ferroelectric Pumping for Self-Powered Cathodic Photoelectrochemical Immunoassay. Analytical chemistry · 19 Jun 2026 PMID 42319751
- Glycoproteome Profiling of Human Serum for Hepatocellular Carcinoma Biomarker Discovery. Journal of proteome research · 17 Jun 2026 PMID 42304605
- Simultaneous multi-biomarker detection: streptavidin-biotin mediated high-quality quantum dot immunosensor with signal amplification. Analytica chimica acta · 26 May 2026 PMID 42191297
- DNA Tetrahedron-Mediated Sensing Platform on a Single Gold Nanowire: Special Signal Amplification, Self-Referencing Capability, and Cross-Validated Exosome Detection for Liver Cancer Liquid Biopsy. ACS sensors · 26 May 2026 PMID 42190059
Preclinical: animal, cell and lab studies (1)
- Glycoprotein biosensor boosted by signal amplification of heparin polysaccharide and insights into glycan-lectin recognition. Mikrochimica acta · 22 May 2026 PMID 42174235
Unclassified: not yet indexed with MeSH (2)
- Integrative Proteomics-Metabolomics Profiling of Umbilical Cord Plasma With Machine Learning Reveals Candidate Biomarkers for Gestational Diabetes Mellitus. Diabetes, obesity & metabolism · 17 Aug 2026 PMID 42608332
- A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice. Journal of controlled release : official journal of the Controlled Release Society · 13 Jul 2026 PMID 42442546
Written from 18 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-15 by GPT. Drafted by language models from published abstracts; not medical advice.